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Abstract. Since 1990 it has been known that dimers are 
the basic functional form of nearly all G-protein-coupled 
receptors (GPCRs) and that homo- and heterodimeriza-
tion may play a key role in correct receptor maturation 
and trafficking to the plasma membrane. Nevertheless, 
homo- and heterodimerization of GPCR has become a 
matter of debate especially in the search for the precise 
physiological meaning of this phenomenon. This article 
focuses on how heterodimerization of adenosine A1 and 
A2A receptors, which are coupled to apparently opposite 
signalling pathways, allows adenosine to exert a fine-tun-
ing modulation of striatal glutamatergic neurotransmis-
sion, providing a switch mechanism by which low and 
high concentrations of adenosine inhibit and stimulate, 
respectively, glutamate release.
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The pharmacological study of membrane receptors largely 
relies on the study of individual receptors that are thought 
to signal in a largely independent manner. However, this 
simplistic view is being challenged by the increasing rec-
ognition that several receptors do not signal as individual 
units, but rather as part of more complex networks that 
are based on the physical association of different recep-
tor proteins. These ‘receptosomes’ confer novel regula-
tory properties to signal reception units, which may be 
accompanied by novel and still largely unexplored phar-
macological and physiopathological properties.
The first proposal for the formation of receptor dimers 
was made in 1979–1980. When searching for an explana-
tion of where all the recently discovered neuropeptides 
in the brain could integrate their messages with those of 
classical transmitters such as the monoamines, it was pos-
tulated that an intramembrane interaction between neuro-
peptide and monoamine receptors could be involved. The 
first observations were published in the early 1980s and 
showed that substance P could modulate the high-affinity 
serotonin (5HT) binding sites in spinal cord membrane 
preparations using biochemical binding techniques [1]. 
Since then, the existence of heterodimers of several G-
protein-coupled receptors (GPCRs) has been reported [2], 
using an increasing number of biochemical and biophysi-
cal techniques. These have revealed the possibility that 
GPCR for different ligands may be physically associated, 
forming heterodimers that allow a tight mutual control of 
the signalling mediated by the two receptors [2]. Interest-
ingly, it has also been noted that GPCRs which are acti-
vated by the same ligand could also form dimers. In some 
cases, this dimerization is essential for receptor function, 
as occurs for the GABAB receptor [3] and for the amino 
acid taste receptors [4]. Heterodimers formed by recep-
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tors activated by the same ligand have also been described 
for members of the family of muscarinic acetylcholine 
receptors [5], adrenergic receptors [6], dopamine recep-
tors [7] and opioid receptors [8]. However, apart from the 
heterodimerization of the delta and kappa opioid peptide 
receptors that occurs in a tissue-specific manner (namely 
in the spinal cord) and was proposed to be a spinal-selec-
tive target for tissue-selective analgesics [8], the possible 
physiopathological role of these heterodimers of GPCRs 
of the same family remains largely undefined. We will 
now review the evidence we have gathered for the forma-
tion of heterodimers composed of adenosine A1 and A2A 
receptors and discuss the relevance of this dimer for the 
control that adenosine exerts on glutamate release from 
corticostriatal afferent fibres.
Adenosine is a molecule that plays a key regulatory role 
in the nervous system since its extracellular concentra-
tion rises as a function of neuronal activity, acting as a 
workload or energy-dependent neuromodulator through 
combined presynaptic, postsynaptic and non-synaptic 
actions [9, 10]. Extracellular adenosine regulates several 
central functions including neuronal viability, neuronal 
membrane potential, propagation of action potentials, 
astrocytic functions, microglia reactivity, primary me-
tabolism in both neurons and astrocytes and blood flow 
[10]. Adenosine mediates its actions through activation of 
specific GPCRs, for which four subtypes have been iden-
tified (A1R, A2AR, A2BR and A3R) [11]. The most abun-
dant adenosine receptor in many regions is the inhibitory 
A1R which is functionally coupled to members of the 
pertussis-toxin-sensitive family of G proteins (Gi1, Gi2, 
Gi3 and Go) and whose activation regulates the activity 
of membrane and intracellular proteins such as adenylate 
cyclase, Ca2+ channels, K+ channels and phospholipase C 
[12]. In central neuronal tissue, adenosine can also signal 
through the activation of A2AR, which is coupled mostly 
to GS proteins [10], thus being mainly linked to adenylyl 
cyclase activation and the protein kinase A (PKA)-depen-
dent signalling cascades. As the A1R and A2AR operate 
through opposite signal transduction pathways, they have 
always been considered as isolated entities in the context 
of adenosine neuromodulation. However, there is already 
good evidence to conceive a role for dimers involving 
adenosine receptors in the context of neuromodulation. 
In fact, adenosine receptors have been shown to form 
homodimers [13, 14], which are believed to be the func-
tional receptor species placed at the cell surface [14], and 
also heterodimers with other GPCRs. For example, A1R 
has been found to heterodimerize with the dopamine D1 
receptor (D1R), this phenomenon being essential for dif-
ferential desensitization mechanisms and for receptor 
trafficking [15]. Heterodimers of A1R with metabotropic 
glutamate receptor 1α (mGlu1α) seem to play a key role 
in preventing glutamate excitotoxicity [16], whereas the 
physiological role for the proven heterodimerization of 
A1R and purinergic P2Y1 receptor (P2Y1R) has not yet 
been elucidated [17]. On the other hand, A2AR also has 
the ability to heterodimerize with the dopamine D2 recep-
tor (D2R) [18, 19], this heterodimerization being the mo-
lecular basis for the antagonistic interactions that regulate 
the function of the GABAergic enkephalinergic neurons 
[20]. A2AR also heterodimerizes with the metabotropic 
glutamate receptor 5 (mGlu5) [21], giving rise to a syn-
ergistic functional interaction demonstrated both at the 
biochemical and behavioural levels [20].
The existence of these dimeric forms involving either 
A1Rs or A2ARs has not altered the widespread acceptance 
that these two adenosine receptors with opposite physi-
ological functions signal independently. Unexpectedly, 
however, A1R and A2AR are coexpressed in a variety of 
cells, as in glutamatergic neurons of the hippocampus [22] 
and striatum [23]. Furthermore, some evidence indicates 
a potential interaction between A1Rs and A2ARs [24–26], 
suggesting the possibility that these receptors establish a 
molecular and/or functional cross-talk, i.e. as if they were 
part of the same molecular transduction complex or sig-
nalosome. The formation of A1R-A2AR heterodimers in 
mammalian cells and in striatal glutamatergic nerve ter-
minals was recently demonstrated using a combination of 
approaches, including radioligand-binding experiments, 
coimmunoprecipitation, bioluminescence resonance en-
ergy transfer and time-resolved fluorescence resonance 
energy transfer techniques [23]. Exploration of the sig-
nalling properties of this novel heterodimer suggests that 
it may constitute the molecular basis implicated in the 
functional cross-talk between these two receptors, afford-
ing a logical and economical device to fine-tune adenos-
ine neuromodulation.
Radioligand-binding experiments reveal that the forma-
tion of the A1R-A2AR heteromer in a heterologous expres-
sion system does not modify the affinity of the A1Rs or 
A2ARs for their respective agonists. Interestingly, the af-
finity of the A1R for its agonist decreases when the A2AR 
is activated, but the activation of the A1R does not alter 
A2AR binding characteristics. Thus, in the heterodimer, 
A1R responsiveness to agonist is modulated by the A2AR, 
whereas the latter preserves its own binding signature, 
indicating that A2ARs can control A1R functionality, but 
not vice versa. This ability of A2ARs to control A1Rs in the 
A1R-A2AR heterodimer was further confirmed function-
ally. In fact, upon formation of the A1R-A2AR heterodimer, 
activation of the A2AR decreases A1R-mediated effects, as 
shown by the significant reduction in the A1R-induced in-
tracellular calcium peak obtained by preincubation with a 
selective A2AR agonist [23].
The question still remained as to whether the formation 
of this A1R-A2AR heterodimer might play a physiological 
role in native brain preparations. This question is of major 
relevance since the involvement of GPCR heterodimers 
in pathophysiological processes remains poorly explored 
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despite substantial evidence for their presence in native 
brain preparations. We will first review the evidence in-
dicating the existence of A1R-A2AR dimers in brain tissue 
and then critically review their possible functional role.
The distribution of A1R and A2AR overlaps in some brain 
areas, namely in dopamine-rich regions [27, 28]. We have 
recently demonstrated the presence of both A1R and A2AR 
in the same glutamatergic nerve terminals, both in the 
hipppocampus [22] and striatum [23]. Ultrastructural 
analysis by means of immunolelectron microscopy of 
A1R and A2AR distribution in striatum reveals that these 
receptors codistribute and colocalize in striatal gluta-
matergic synapses [23]. Glutamatergic terminals in the 
striatum establish synaptic contacts with the dendritic 
spines of the GABAergic efferent neurons, which are 
subdivided into enkephalinergic and dynorphinergic neu-
rons. The A2AR is known to be abundantly expressed by 
the GABAergic enkephalinergic neurons [2]. Thus, at the 
postsynaptic site, A2ARs are located along the extrasyn-
aptic plasma membrane and in a perisynaptic ring sur-
rounding the postsynaptic density [23]. A1Rs, which are 
known to be expressed by both GABAergic enkephalin-
ergic and dynorphinergic neurons [10], were also local-
ized postsynaptically at glutamatergic synapses. A1R and 
A2AR colocalize at the postsynaptic and at the presynaptic 
level, often being found intrasynaptically, in the active 
zone [23]. Despite this heterogenous distribution of both 
A1Rs and A2ARs intra- and extrasynaptically in synapses 
between glutamatergic corticostriatal projections, the im-
munocytochemistry results together with the coimmuno-
precipitation experiments clearly showed that the striatal 
A1R-A2AR heteromer is preferentially localized in the 
striatal glutamatergic terminals at both presypnatic and 
postsynaptic levels.
In excitatory glutamatergic synapses, the most accepted 
role for adenosine is the inhibition of synaptic transmis-
sion through activation of presynaptic A1Rs, the proto-
typical inhibitory Gi/o-protein-coupled receptor whose 
stimulation decreases the probability of neurotransmitter 
release [29]. As previously discussed [30], this predomi-
nant ability to record A1R-mediated inhibition of excit-
atory transmission mainly results from the experimental 
design requiring the attainment of robust signals hardly 
prone to be further facilitated, together with pharmaco-
logical agents largely selective for A1Rs rather than for 
A2ARs. In fact, the use of particular stimulating condi-
tions together with pharmacological tools with adequate 
selectivity to interfere with A2ARs has made possible the 
identification of a parallel ability of adenosine to facili-
tate the evoked glutamate release via activation of pre-
synaptic A2ARs [20]. The obvious question is: how does 
adenosine choose between A1R and A2ARs in the glutama-
tergic nerve terminal to control the glutamate release? To 
answer this question we need first to understand several 
important assumptions concerning A1R and A2ARs. First, 
these receptors have different affinities for endogenous 
adenosine, with the A1R showing a higher affinity than the 
A2AR [31]. Thus, at moderate adenosine concentrations 
preferential A1R stimulation occurs and glutamate release 
is inhibited. In contrast, when adenosine reaches concen-
Figure 1. Scheme showing differences in the efficacy of adenosine to stimulate A1Rs and A2ARs in the A1R-A2AR heterodimers. Low 
concentrations of adenosine activate predominantly A1Rs, inhibiting glutamate release. High concentrations of adenosine also activate 
A2ARs, which, by means of the A1R-A2AR intramembrane interaction (red arrow), antagonizes A1R function, therefore facilitating glutamate 
release.
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trations high enough to stimulate the A2AR, glutamate 
release is enhanced [20]. However, in this scenario, the 
A1R would be maximally effective and should effectively 
counteract any attempts of A2ARs to facilitate glutamate 
release. How can this conflict be eliminated? The data 
we obtained measuring the evoked release of glutamate 
from striatal nerve terminals indicate that the functional 
properties of the A1R-A2AR heteromer allow resolution of 
this issue since A1R responsiveness in the heterodimer is 
under the control of A2ARs. Thus, we showed that the pre-
dominant A1R-mediated inhibition of glutamate release 
can be abrogated by preincubation with an A2AR agonist, 
and simultaneous activation of A1Rs and A2ARs always 
leads to predominant facilitation of the evoked release of 
glutamate. Furthermore, increasing concentrations of the 
natural ligand, adenosine, first trigger an inhibitory effect 
at lower concentrations, which is reverted to a facilitatory 
effect with increasing concentrations. This leads to the 
conclusion that the A1R-A2AR heteromerization provides 
a basic mechanism to select the pattern of adenosine neu-
romodulation in striatum based on the intramembrane re-
ceptor-receptor communication allowing A2ARs to block 
the A1R inhibitory function. Thus, the regulation of gluta-
mate release by adenosine switches from inhibition to fa-
cilitation thanks to the A1R-A2AR heterodimer, in a man-
ner dependent on extracellular adenosine levels [23].
Concluding remarks
At a relatively low concentration, extracellular ad-
enosine preferentially stimulates A1Rs, which display a 
higher affinity for adenosine than A2ARs. A preferential 
A1R stimulation in glutamatergic nerve terminals inhib-
its glutamatergic neurotransmission. On the other hand, 
under conditions of robust production of extracellular 
adenosine in striatum, adenosine A2A receptor activation 
in the existing A1R-A2AR heterodimers would limit A1R- 
mediated function, the outcome being a facilitation of the 
evoked release of glutamate (Fig. 1). Thus, the A1R-A2AR 
heterodimer exerts a fine-tuning modulation of glutama-
tergic neurotransmission in striatum, providing a switch 
mechanism by which low and high concentrations of 
adenosine inhibit and stimulate, respectively, glutamate 
release. Heterodimerization of different receptors for the 
same neurotransmitter constitutes a rationale to understand 
how, depending on its concentration, a given neurotrans-
mitter may facilitate or inhibit neural transmission.
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